Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference
06 November 2007 - 11:30PM
PR Newswire (US)
-Presentation available by web cast- TORONTO, Nov. 6
/PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. ('Lorus'), a
biopharmaceutical company specializing in the research, development
and commercialization of pharmaceutical products and technologies
for the management of cancer, announced today that on Wednesday,
November 7, 2007, at 10:30 a.m. EST (Eastern Standard Time), Dr.
Aiping H. Young, President and CEO will present a corporate
overview of the Company at the Acumen BioFin Rodman and Renshaw 9th
Annual Healthcare Conference. The presentation will be web cast at
http://www.wsw.com/webcast/rrshq12/lrp and will be available
through the Lorus website from November 7, 2007. The conference,
which runs from November 5 to November 7, 2007, provides
informational service and networking opportunities for healthcare
companies and investors. About Lorus Lorus is a biopharmaceutical
company focused on the research and development of cancer
therapies. Lorus' goal is to capitalize on its research,
preclinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination,
to successfully manage cancer. Through its own discovery efforts
and an acquisition and in-licensing program, Lorus is building a
portfolio of promising anticancer drugs. Late-stage clinical
development and marketing may be done in cooperation with strategic
pharmaceutical partners. Lorus currently has products in human
clinical trials with a pipeline of seven clinical trials in Phase
II clinical trial programs, as well as one Phase II and one Phase
III clinical trial recently completed. Lorus Therapeutics Inc. is a
public company listed on the Toronto Stock Exchange under the
symbol LOR, and on the American Stock Exchange under the symbol
LRP. Virulizin(R) is a registered trademark of Lorus Therapeutics
Inc. Forward Looking Statements Except for historical information,
this press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
which reflect the Company's current expectation and assumptions,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated.
These forward-looking statements involve risks and uncertainties,
including, but not limited to, changing market conditions, the
Company's ability to obtain patent protection and protect its
intellectual property rights, commercialization limitations imposed
by intellectual property rights owned or controlled by third
parties, intellectual property liability rights and liability
claims asserted against the Company, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability
to attract and retain business partners and key personnel, future
levels of government funding, the Company's ability to obtain the
capital required for research, operations and marketing and other
risks detailed from time-to-time in the Company's ongoing quarterly
filings, annual information forms, annual reports and 40-F filings.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. Lorus Therapeutics Inc.'s press
releases are available through the Company's Internet site:
http://www.lorusthera.com/. DATASOURCE: Lorus Therapeutics Inc.
CONTACT: Enquiries: Lorus Therapeutics Inc., Dr. Saeid Babaei,
(416) 798-1200 ext. 490,
Copyright